Alzheimer
Navigation Links
Alzheimer at medicine technology
Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease
Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 26, 2007 - SirtrisPharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical companyfocused on discovering and developing small molecule drugs to treatdiseases of aging, announced today that activation of SIRT1, amember of the sirtuin family of enzymes, was shown to protectagainst neurodegenerative diseases such as Alzheimer's Disease andAmyotrophic Lat...
BROOMFIELD, Colo., June 11, 2007 /PRNewswire/ -- Accera, Inc.today is presenting data from an open-label extension of its PhaseIIb clinical trial of AC-1202 (Ketasyn) in Alzheimer's disease (AD)at the Alzheimer's Association's International Conference onPrevention of Dementia in Washington, D.C. Consistent with thefindings of earlier clinical and preclinical studies, AC-1202 wasshown to...
WASHINGTON, DC, June 11, 2007 /PRNewswire-FirstCall/ - Paul S.Aisen, M.D., Professor of Neurology and Medicine at GeorgetownUniversity Medical Center, and principal investigator in the UnitedStates of Neurochem Inc.'s North American Phase III clinical trialfor tramiprosate (ALZHEMED(TM)) will present today an update onNeurochem's investigational product candidate for the treatment ofAlzh...
SALT LAKE CITY, UT, June 11, 2007 (MARKET WIRE via COMTEX NewsNetwork) -- Myriad Genetics, Inc. (NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com )announced today that it presented a mathematical comparison of a"Staggered Start" and a "Randomized Withdrawal" clinical trialdesign with a "Natural History Staggered Start" clinical trialdesign at the Alzheime...
Treating Heart Disease Risk Factors May Slow Alzheimer's Disease Progression
- Late Life Weight Loss and "Motivational Reserve" May Also AffectAlzheimer's Risk - WASHINGTON, June 10, 2007 /PRNewswire-USNewswire/ -- A new studysuggests that treating risk factors for heart disease and stroke,such as high blood pressure and diabetes, may slow the progressionof Alzheimer's disease, according to research reported today at the2nd Alzheimer's Association International Co...- Aggregate Benefit over Placebo Larger at One Year than at SixMonths - SAN FRANCISCO and WASHINGTON, June 11, 2007/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that thebenefits of Dimebon over placebo in its double-blind,placebo-controlled Phase 2 study in mild-to- moderate Alzheimer'sdisease were statistically significant on all five study endpointsat 12 months. Importantl...
Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease
Presentation of Final Phase I Monthly Implant and Phase IIa DailyOral Results LAUSANNE, Switzerland, June 11, 2007 /PRNewswire/ -- DebiopharmGroup (Debiopharm), a global independent biopharmaceuticaldevelopment specialist in oncology and serious medical conditions,presented final results of two Debio 9902 (formerly ZT-1) studiesfor the treatment of Alzheimer's disease (AD) at the Alzheime...SAN FRANCISCO, June 05, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that it will hold a teleconferenceat 8:30 a.m. Eastern time on Monday, June 11, to discuss top-line12-month results from its randomized, double-blind,placebo-controlled Phase 2 clinical trial of Dimebon(TM), its leadproduct candidate, in Alzheimer's disease. Rachelle Doody, M.D., Ph.D., lead inve...
Company Conference Call Scheduled for Friday, May 4, at 9:00 a.m.Eastern Time to Discuss Data SAN FRANCISCO, May 03, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that new data from the mild andmoderate subgroups of Alzheimer's disease patients in the Company'ssix-month Phase 2 efficacy study of Dimebon showed that bothsubgroups were improved compared with placebo-treated...
Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the Treatment of Alzheimer's Disease
SAN DIEGO, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, Inc.today presented interim clinical data from a Phase 1 trial ofCERE-110, a gene therapy product designed to deliver nerve growthfactor (NGF) for the treatment of Alzheimer's disease. After oneyear of follow-up, the results for the six patients who receivedCERE-110 in the trial indicate that a single administration of thetherapy...Samaritan Announces Positive Data in Nonclinical (IND) In- VitroStudies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is pleased to announce positive results were attained with itslate-stage preclinical/nonclinical testing of Caprospinol (SP-233),with well recognized in-vitro models....
BROOMFIELD, Colo., May 01, 2007 /PRNewswire/ -- Accera Inc. ispresenting topline data today from its Phase IIb study of its leadcompound AC-1202 in Alzheimer's disease (AD) at the AmericanAcademy of Neurology (AAN) 59th Annual Meeting in Boston. Judged bythe AAN to be in the top five percent of the program, the data willalso be featured in the Scientific Highlights Plenary Session. <p...
Cortex Area Thinner in Youth with Alzheimers-Related Gene
BETHESDA, Md., April 23, 2007--A part of the brain firstaffected by Alzheimers disease (<a target="_blank" href="http://www.nia.nih.gov/Alzheimers/">http://www.nia.nih.gov/Alzheimers/ )is thinner in youth with a risk gene for the disorder, a brainimaging study by researchers at the National Institute of MentalHealth (NIMH), one of the National Institutes of Health (NIH), hasfound. A t...BROOMFIELD, Colo., April 24, 2007 /PRNewswire/ -- Accera Inc.announced today that topline data from its Phase IIb study of itslead compound AC-1202 in Alzheimer's disease (AD) will be presentedat the annual meeting of the American Academy of Neurology (AAN) inBoston. Judged by the AAN to be in the top five percent of theprogram, the data will also be featured in the ScientificHighlights...
-- New Subset Analyses To Be Presented -- SAN FRANCISCO, April 24, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that data from the Company's Phase2 efficacy study of Dimebon(TM) in Alzheimer's disease will bepresented for the first time in the United States at the AmericanAcademy of Neurology's 59th Annual Meeting in Boston on Thursday,May 3, at 4:15 p.m. Eastern time. T...
Alzheimer's Drug Shows Promise in Fighting Cancer
LOS ANGELES, April 17, 2007 /PRNewswire/ -- Researchers from theBarbara Ann Karmanos Cancer Institute in Detroit, MI presentedstrong evidence today that an antibiotic typically prescribed forAlzheimer's patients could be effective in eventually treatingcertain types of cancers. Q. Ping Dou, Ph.D., leader, Prevention Program at Karmanos, andmembers of his lab announced the findings...In Vitro Assays Show rBChE Suppresses Amyloid PlaqueFormation ANNAPOLIS, Md., April 3, 2007 - PharmAthene, Inc., a leadingbiodefense company specializing in the development andcommercialization of medical countermeasures against chemical andbiological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently presented...
Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's Conference
VANCOUVER, British Columbia--(BUSINESS WIRE)--Apr 3, 2007 - AllonTherapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM),announced today the publication of new preclinical data fromadditional confirmatory animal studies showing that Allon's productcandidate AL-108 significantly reduces the accumulation of amyloidpeptide and the hyperphosphorylation of tau protein in the brain,two path...In Vitro Assays Show rBChE Suppresses Amyloid Plaque Formation ANNAPOLIS, Md., April 03, 2007 /PRNewswire/ -- PharmAthene,Inc., a leading biodefense company specializing in the developmentand commercialization of medical countermeasures against chemicaland biological terrorism, announced today that new data from itsrecombinant butyrylcholinesterase (rBChE) research program wererecently pr...
And Japanese Study Suggests the Drug Improves Memory SARASOTA, Fla., March 22, 2007 /PRNewswire-FirstCall/ -- TheRoskamp Institute announced today that it has received positivepreliminary results in its major clinical study that is testing apromising new drug application for the treatment of Alzheimer'sdisease. The clinical study, which was first announced inSeptember, is the first human...
Alzheimer's Growth Shows Need for Increased FDA Funding
Coalition for a Stronger FDA says drug review programs need moremoney WASHINGTON, March 21, 2007 /PRNewswire-USNewswire/ -- A newestimate by the Alzheimer's Association shows that more than fivemillion Americans are living with Alzheimer's disease -- a 10percent growth over previous estimates and a number that could morethan triple in the coming decades unless new treatments and curesare...PHILADELPHIA--(BUSINESS WIRE)--Mar 19, 2007 - AvidRadiopharmaceuticals, Inc. (Avid), a product-focused molecularimaging company, today announced the presentation of the firstresults from a clinical study of 18F-AV-1/ZK (AV-1), a novelradiopharmaceutical for positron emission tomography (PET) imagingof amyloid plaques in patients with Alzheimer's disease. Principalinvestigator Dr. Christophe...
SAN FRANCISCO, March 19, 2007 /PRNewswire-FirstCall/ --Medivation, Inc. today announced that six-month results from itsrandomized, double-blinded, placebo-controlled Phase 2 efficacytrial of Dimebon(TM) in patients with mild-to-moderate Alzheimer'sdisease demonstrated that patients treated with Dimebon weresignificantly improved compared to patients taking placebo on allfive efficacy end...
Other TagsaimedretiregradgradgradgradgradOther Contentsexonsexonsexonsexonsexoskeletonexoskeletonexonucleaseexonucleaseexonucleaseexpressexpressexpressexpressexpressexpressexpressexpressextantextantextensor
(Date:10/6/2008)...earch study funded by JDRF suggests that a common ...om developing type 1 diabetes. The findings provid...why type 1 diabetes develops in people, and may le...is week in Nature Magazine, lends further suppor... appropriate amount and composition of bacteria ma...
(Date:10/6/2008)...t project results are announced this week at the W...ere will be at least seven Texas species on the gl... from Texas that are classified as under some leve...monly known as Mexican long-tongued bat, Mexican l...desert pocket gopher, Texas kangaroo rat, and bann...
(Date:10/6/2008)...Laboratory (CSHL) is clarifying a previously unapp... in cancer. , Last year, scientists from the sa...alled SF2/ASF--a protein that changes the instruct...uce tumors in cell cultures. The team,s newly publ...erstood, this same splicing factor acts on a group...
(Date:10/6/2008)...ferent kinds of cells have in common with a mixtur...th mixtures to separate into two distinct regions....onal computer model of the cell sorting process pr...sics at Vanderbilt University, and his colleagues ...scribed in the Oct. 3 issue of the journal Physic...
Breaking Biology News(10 mins):JDRF funded study links 'hygiene hypothesis' to diabetes prevention 27 Texas mammals listed as threatened on Global Mammal Assessment 2Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 2Surface tension drives segregation within cell mixtures 2Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts 25542 1Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts 25542 2Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts 25542 3Waters SYNAPT HDMS and Xevo TQ MS Recognized for Mass Spectrometry Innovation by Industry Experts 25542 4Gerbig Engineering Introduces New Product Feature 25539 1Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 1Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 2Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 3Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 4Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 5Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 6Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 7Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 8Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 9Bavarian Nordic A S Interim Report for the Period 1 January to 30 June 2008 7209 10Ultrasound used to predict heart attack risk 25534 1Ultrasound used to predict heart attack risk 25534 2(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |